You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDebrisoquin
Accession NumberDB04840
TypeSmall Molecule
GroupsApproved
DescriptionAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism. [PubChem]
Structure
Thumb
Synonyms
Debrisochinum
Debrisoquin
Debrisoquina
Debrisoquine
Debrisoquinum
Isocaramidine
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Bonipresslkapharm
DeclinaxRoche
TendorChinoin
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Debrisoquin sulfate
581-88-4
Thumb
  • InChI Key: CAYGYVYWRIHZCQ-UHFFFAOYSA-N
  • Monoisotopic Mass: 448.189274104
  • Average Mass: 448.539
DBSALT000370
Categories
UNIIX31CDK040E
CAS number1131-64-2
WeightAverage: 175.2303
Monoisotopic: 175.110947431
Chemical FormulaC10H13N3
InChI KeyInChIKey=JWPGJSVJDAJRLW-UHFFFAOYSA-N
InChI
InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12)
IUPAC Name
1,2,3,4-tetrahydroisoquinoline-2-carboximidamide
SMILES
NC(=N)N1CCC2=CC=CC=C2C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as tetrahydroisoquinolines. These are tetrahydrogenated isoquinoline derivatives.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassTetrahydroisoquinolines
Sub ClassNot Available
Direct ParentTetrahydroisoquinolines
Alternative Parents
Substituents
  • Tetrahydroisoquinoline
  • Benzenoid
  • Tertiary amine
  • Guanidine
  • Azacycle
  • Carboximidamide
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Imine
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of moderate and severe hypertension, either alone or as an adjunct, and for the treatment of renal hypertension.
PharmacodynamicsDebrisoquin is an adrenergic neuron-blocking drug similar in effects to guanethidine. It is a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize this and many other clinically important drugs. They are commonly referred to as having a debrisoquin 4-hydroxylase polymorphism.
Mechanism of actionDebrisoquin acts at the sympathetic neuroeffector junction by inhibiting or interfering with the release and/or distribution of norepinephrine, rather than acting at the effector cell by inhibiting the association of norepinephrine with its receptors. It is taken up by norepinephrine transporters. It becomes concentrated in NE transmitter vesicles, replacing NE in these vesicles. This leads to a gradual depletion of NE stores in the nerve endings. Once inside the terminal it blocks the release of noradrenaline in response to arrival of an action potential. In contrast to ganglionic blocking agents, debrisoquin suppresses equally the responses mediated by alpha-and beta-adrenergic receptors but does not produce parasympathetic blockade. Since sympathetic blockade results in modest decreases in peripheral resistance and cardiac output, debrisoquin lowers blood pressure in the supine position. It further reduces blood pressure by decreasing the degree of vasoconstriction that normally results from reflex sympathetic nervous activity upon assumption of the upright posture, thus reducing venous return and cardiac output more.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9714
Blood Brain Barrier+0.9106
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.8427
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterInhibitor0.8817
CYP450 2C9 substrateNon-substrate0.8429
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.7101
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9549
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9532
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9462
Ames testNon AMES toxic0.7018
CarcinogenicityNon-carcinogens0.976
BiodegradationNot ready biodegradable0.9422
Rat acute toxicity2.7479 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6904
hERG inhibition (predictor II)Inhibitor0.5928
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point278-280 °CPhysProp
logP0.75SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.842 mg/mLALOGPS
logP0.58ALOGPS
logP1.07ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)12.47ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area53.11 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity63.85 m3·mol-1ChemAxon
Polarizability19.48 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Wenner,W.; U.S. Patent 3,157,573; November 17,1964; assigned to Hoffmann-LaRoche, Inc.

General ReferencesNot Available
External Links
ATC CodesC02CC04
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Debrisoquin.
AbirateroneThe metabolism of Debrisoquin can be decreased when combined with Abiraterone.
AcebutololAcebutolol may increase the hypotensive activities of Debrisoquin.
AcetaminophenThe serum concentration of Debrisoquin can be increased when it is combined with Acetaminophen.
AfatinibThe serum concentration of Debrisoquin can be increased when it is combined with Afatinib.
AlbendazoleThe serum concentration of Debrisoquin can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Debrisoquin can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Debrisoquin can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Debrisoquin can be increased when it is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the hypotensive activities of Debrisoquin.
AliskirenDebrisoquin may increase the hypotensive activities of Aliskiren.
AlprenololAlprenolol may increase the hypotensive activities of Debrisoquin.
AmantadineThe serum concentration of Debrisoquin can be increased when it is combined with Amantadine.
AmbrisentanDebrisoquin may increase the hypotensive activities of Ambrisentan.
AmifostineDebrisoquin may increase the hypotensive activities of Amifostine.
Aminohippuric acidThe serum concentration of Debrisoquin can be increased when it is combined with Aminohippuric acid.
AmiodaroneThe serum concentration of Debrisoquin can be decreased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Debrisoquin can be increased when it is combined with Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Debrisoquin.
AmprenavirThe serum concentration of Debrisoquin can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Debrisoquin can be increased when it is combined with Amsacrine.
ArtemetherThe metabolism of Debrisoquin can be decreased when combined with Artemether.
AstemizoleThe serum concentration of Debrisoquin can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Debrisoquin can be increased when it is combined with Atazanavir.
AtenololAtenolol may increase the hypotensive activities of Debrisoquin.
AtomoxetineThe metabolism of Debrisoquin can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Debrisoquin can be increased when it is combined with Atorvastatin.
AzelastineThe serum concentration of Debrisoquin can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Debrisoquin can be increased when it is combined with Azithromycin.
BenazeprilBenazepril may increase the hypotensive activities of Debrisoquin.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Debrisoquin.
BenmoxinBenmoxin may increase the hypotensive activities of Debrisoquin.
BenzocaineThe serum concentration of Debrisoquin can be increased when it is combined with Benzocaine.
BepridilBepridil may increase the hypotensive activities of Debrisoquin.
BetaxololBetaxolol may increase the hypotensive activities of Debrisoquin.
BethanidineBethanidine may increase the hypotensive activities of Debrisoquin.
BimatoprostBimatoprost may increase the hypotensive activities of Debrisoquin.
BiperidenThe serum concentration of Debrisoquin can be increased when it is combined with Biperiden.
BisoprololBisoprolol may increase the hypotensive activities of Debrisoquin.
BosentanBosentan may increase the hypotensive activities of Debrisoquin.
BosutinibThe serum concentration of Debrisoquin can be increased when it is combined with Bosutinib.
BretyliumBretylium may increase the hypotensive activities of Debrisoquin.
BrimonidineDebrisoquin may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Debrisoquin.
BromocriptineThe serum concentration of Debrisoquin can be increased when it is combined with Bromocriptine.
BupranololDebrisoquin may increase the hypotensive activities of Bupranolol.
BuprenorphineThe serum concentration of Debrisoquin can be increased when it is combined with Buprenorphine.
BupropionThe metabolism of Debrisoquin can be decreased when combined with Bupropion.
BuspironeThe serum concentration of Debrisoquin can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Debrisoquin can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Debrisoquin can be increased when it is combined with Caffeine.
CanagliflozinThe serum concentration of Debrisoquin can be increased when it is combined with Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Debrisoquin.
CandoxatrilCandoxatril may increase the hypotensive activities of Debrisoquin.
CaptoprilCaptopril may increase the hypotensive activities of Debrisoquin.
CarbamazepineThe serum concentration of Debrisoquin can be decreased when it is combined with Carbamazepine.
CaroxazoneCaroxazone may increase the hypotensive activities of Debrisoquin.
CarteololCarteolol may increase the hypotensive activities of Debrisoquin.
CarvedilolCarvedilol may increase the hypotensive activities of Debrisoquin.
CaspofunginThe serum concentration of Debrisoquin can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Debrisoquin can be decreased when combined with Celecoxib.
CeliprololDebrisoquin may increase the hypotensive activities of Celiprolol.
ChloroquineThe serum concentration of Debrisoquin can be increased when it is combined with Chloroquine.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Debrisoquin.
ChlorpromazineThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Debrisoquin can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Debrisoquin can be increased when it is combined with Chlorprothixene.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Debrisoquin.
CholecalciferolThe metabolism of Debrisoquin can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Debrisoquin can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Debrisoquin can be decreased when it is combined with Cholic Acid.
CilazaprilCilazapril may increase the hypotensive activities of Debrisoquin.
CimetidineThe serum concentration of Debrisoquin can be decreased when it is combined with Cimetidine.
CinacalcetThe metabolism of Debrisoquin can be decreased when combined with Cinacalcet.
CiprofloxacinThe serum concentration of Debrisoquin can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Debrisoquin can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Debrisoquin can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Debrisoquin can be decreased when combined with Clemastine.
ClobazamThe metabolism of Debrisoquin can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Debrisoquin can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Debrisoquin can be increased when it is combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Debrisoquin.
ClotrimazoleThe serum concentration of Debrisoquin can be decreased when it is combined with Clotrimazole.
ClozapineThe metabolism of Debrisoquin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Debrisoquin can be increased when it is combined with Cobicistat.
CocaineThe metabolism of Debrisoquin can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Debrisoquin can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Debrisoquin can be increased when it is combined with Colforsin.
CrizotinibThe serum concentration of Debrisoquin can be increased when it is combined with Crizotinib.
CryptenamineCryptenamine may increase the hypotensive activities of Debrisoquin.
CyclophosphamideThe serum concentration of Debrisoquin can be increased when it is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Debrisoquin can be decreased when it is combined with Cyclosporine.
CyclothiazideCyclothiazide may increase the hypotensive activities of Debrisoquin.
DaclatasvirThe serum concentration of Debrisoquin can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Debrisoquin can be increased when it is combined with Dactinomycin.
DarifenacinThe metabolism of Debrisoquin can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Debrisoquin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Debrisoquin can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Debrisoquin can be decreased when it is combined with Daunorubicin.
DelavirdineThe metabolism of Debrisoquin can be decreased when combined with Delavirdine.
DeserpidineDebrisoquin may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Debrisoquin can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Debrisoquin can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Debrisoquin can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Debrisoquin can be increased when it is combined with Dextromethorphan.
DiazoxideDiazoxide may increase the hypotensive activities of Debrisoquin.
DiclofenacThe serum concentration of Debrisoquin can be increased when it is combined with Diclofenac.
DigoxinThe serum concentration of Debrisoquin can be decreased when it is combined with Digoxin.
DihydroergotamineThe serum concentration of Debrisoquin can be increased when it is combined with Dihydroergotamine.
DiltiazemDiltiazem may increase the hypotensive activities of Debrisoquin.
DiphenhydramineThe metabolism of Debrisoquin can be decreased when combined with Diphenhydramine.
DipyridamoleThe serum concentration of Debrisoquin can be increased when it is combined with Dipyridamole.
DorzolamideDorzolamide may increase the hypotensive activities of Debrisoquin.
DoxazosinDoxazosin may increase the hypotensive activities of Debrisoquin.
DoxepinThe serum concentration of Debrisoquin can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Debrisoquin can be decreased when it is combined with Doxorubicin.
DronabinolThe serum concentration of Debrisoquin can be increased when it is combined with Dronabinol.
DronedaroneThe serum concentration of Debrisoquin can be increased when it is combined with Dronedarone.
DuloxetineThe metabolism of Debrisoquin can be decreased when combined with Duloxetine.
EfonidipineDebrisoquin may increase the hypotensive activities of Efonidipine.
ElbasvirThe serum concentration of Debrisoquin can be increased when it is combined with Elbasvir.
EliglustatThe metabolism of Debrisoquin can be decreased when combined with Eliglustat.
EnalaprilEnalapril may increase the hypotensive activities of Debrisoquin.
EnalaprilatDebrisoquin may increase the hypotensive activities of Enalaprilat.
EnzalutamideThe serum concentration of Debrisoquin can be increased when it is combined with Enzalutamide.
EpoprostenolEpoprostenol may increase the hypotensive activities of Debrisoquin.
EprosartanEprosartan may increase the hypotensive activities of Debrisoquin.
ErgonovineThe serum concentration of Debrisoquin can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Debrisoquin can be increased when it is combined with Ergotamine.
ErythromycinThe serum concentration of Debrisoquin can be decreased when it is combined with Erythromycin.
EstramustineThe serum concentration of Debrisoquin can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Debrisoquin can be decreased when it is combined with Estriol.
EstroneThe serum concentration of Debrisoquin can be decreased when it is combined with Estrone.
EtoposideThe serum concentration of Debrisoquin can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Debrisoquin can be increased when it is combined with Etravirine.
FelodipineFelodipine may increase the hypotensive activities of Debrisoquin.
FenoldopamFenoldopam may increase the hypotensive activities of Debrisoquin.
FentanylThe serum concentration of Debrisoquin can be increased when it is combined with Fentanyl.
FexofenadineThe serum concentration of Debrisoquin can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Debrisoquin can be increased when it is combined with Fidaxomicin.
FluconazoleThe serum concentration of Debrisoquin can be increased when it is combined with Fluconazole.
FluoxetineThe serum concentration of Debrisoquin can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Debrisoquin can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Debrisoquin can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Debrisoquin can be increased when it is combined with Flurazepam.
FluvoxamineThe serum concentration of Debrisoquin can be increased when it is combined with Fluvoxamine.
FosinoprilFosinopril may increase the hypotensive activities of Debrisoquin.
FurazolidoneFurazolidone may increase the hypotensive activities of Debrisoquin.
GefitinibThe serum concentration of Debrisoquin can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Debrisoquin can be increased when it is combined with Genistein.
GlyburideThe serum concentration of Debrisoquin can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Debrisoquin can be increased when it is combined with Glycerol.
Gramicidin DThe serum concentration of Debrisoquin can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Debrisoquin can be increased when it is combined with Grepafloxacin.
GuanabenzGuanabenz may increase the hypotensive activities of Debrisoquin.
GuanadrelGuanadrel may increase the hypotensive activities of Debrisoquin.
GuanethidineGuanethidine may increase the hypotensive activities of Debrisoquin.
GuanfacineGuanfacine may increase the hypotensive activities of Debrisoquin.
HaloperidolThe serum concentration of Debrisoquin can be increased when it is combined with Haloperidol.
HexamethoniumDebrisoquin may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Debrisoquin.
HydralazineHydralazine may increase the hypotensive activities of Debrisoquin.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Debrisoquin.
HydrocortisoneThe serum concentration of Debrisoquin can be increased when it is combined with Hydrocortisone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Debrisoquin.
IdelalisibThe serum concentration of Debrisoquin can be increased when it is combined with Idelalisib.
IloprostIloprost may increase the hypotensive activities of Debrisoquin.
ImatinibThe serum concentration of Debrisoquin can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Debrisoquin can be increased when it is combined with Imipramine.
IndapamideIndapamide may increase the hypotensive activities of Debrisoquin.
IndenololDebrisoquin may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Debrisoquin can be decreased when it is combined with Indinavir.
IndomethacinThe serum concentration of Debrisoquin can be increased when it is combined with Indomethacin.
IndoraminDebrisoquin may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Debrisoquin.
IproniazidIproniazid may increase the hypotensive activities of Debrisoquin.
IrbesartanIrbesartan may increase the hypotensive activities of Debrisoquin.
IsavuconazoniumThe serum concentration of Debrisoquin can be increased when it is combined with Isavuconazonium.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Debrisoquin.
IsoniazidThe metabolism of Debrisoquin can be decreased when combined with Isoniazid.
IsradipineIsradipine may increase the hypotensive activities of Debrisoquin.
ItraconazoleThe serum concentration of Debrisoquin can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Debrisoquin can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Debrisoquin can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Debrisoquin can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Debrisoquin can be increased when it is combined with Ketoconazole.
LabetalolLabetalol may increase the hypotensive activities of Debrisoquin.
LacidipineDebrisoquin may increase the hypotensive activities of Lacidipine.
LansoprazoleThe serum concentration of Debrisoquin can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Debrisoquin can be increased when it is combined with Lapatinib.
LatanoprostLatanoprost may increase the hypotensive activities of Debrisoquin.
LercanidipineLercanidipine may increase the hypotensive activities of Debrisoquin.
LevofloxacinThe serum concentration of Debrisoquin can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Debrisoquin can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Debrisoquin can be increased when it is combined with Lidocaine.
LiothyronineThe serum concentration of Debrisoquin can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Debrisoquin can be decreased when it is combined with Liotrix.
LisinoprilLisinopril may increase the hypotensive activities of Debrisoquin.
LofexidineDebrisoquin may increase the hypotensive activities of Lofexidine.
LomitapideThe serum concentration of Debrisoquin can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Debrisoquin can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Debrisoquin can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Debrisoquin can be increased when it is combined with Loratadine.
LorcaserinThe metabolism of Debrisoquin can be decreased when combined with Lorcaserin.
LosartanLosartan may increase the hypotensive activities of Debrisoquin.
LovastatinThe serum concentration of Debrisoquin can be increased when it is combined with Lovastatin.
LumacaftorThe serum concentration of Debrisoquin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Debrisoquin can be decreased when combined with Lumefantrine.
MacitentanDebrisoquin may increase the hypotensive activities of Macitentan.
ManidipineDebrisoquin may increase the hypotensive activities of Manidipine.
MaprotilineThe serum concentration of Debrisoquin can be increased when it is combined with Maprotiline.
MebanazineMebanazine may increase the hypotensive activities of Debrisoquin.
MebendazoleThe serum concentration of Debrisoquin can be increased when it is combined with Mebendazole.
MecamylamineMecamylamine may increase the hypotensive activities of Debrisoquin.
MefloquineThe serum concentration of Debrisoquin can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Debrisoquin can be increased when it is combined with Megestrol acetate.
MeprobamateThe serum concentration of Debrisoquin can be increased when it is combined with Meprobamate.
MethadoneThe serum concentration of Debrisoquin can be increased when it is combined with Methadone.
MethotrimeprazineThe metabolism of Debrisoquin can be decreased when combined with Methotrimeprazine.
MethyldopaMethyldopa may increase the hypotensive activities of Debrisoquin.
Methylene blueMethylene blue may increase the hypotensive activities of Debrisoquin.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Debrisoquin.
MetipranololMetipranolol may increase the hypotensive activities of Debrisoquin.
MetolazoneMetolazone may increase the hypotensive activities of Debrisoquin.
MetoprololMetoprolol may increase the hypotensive activities of Debrisoquin.
MibefradilMibefradil may increase the hypotensive activities of Debrisoquin.
MiconazoleThe serum concentration of Debrisoquin can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Debrisoquin can be decreased when it is combined with Midazolam.
MifepristoneThe serum concentration of Debrisoquin can be decreased when it is combined with Mifepristone.
MinaprineMinaprine may increase the hypotensive activities of Debrisoquin.
MinoxidilMinoxidil may increase the hypotensive activities of Debrisoquin.
MirabegronThe metabolism of Debrisoquin can be decreased when combined with Mirabegron.
MitomycinThe serum concentration of Debrisoquin can be increased when it is combined with Mitomycin.
MitoxantroneThe serum concentration of Debrisoquin can be decreased when it is combined with Mitoxantrone.
MoclobemideMoclobemide may increase the hypotensive activities of Debrisoquin.
MoexiprilMoexipril may increase the hypotensive activities of Debrisoquin.
MolsidomineMolsidomine may increase the hypotensive activities of Debrisoquin.
MorphineThe serum concentration of Debrisoquin can be increased when it is combined with Morphine.
MoxonidineDebrisoquin may increase the hypotensive activities of Moxonidine.
NadololNadolol may increase the hypotensive activities of Debrisoquin.
NaltrexoneThe serum concentration of Debrisoquin can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Debrisoquin can be increased when it is combined with Naringenin.
NebivololDebrisoquin may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Debrisoquin can be decreased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Debrisoquin can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Debrisoquin can be increased when it is combined with Neostigmine.
NevirapineThe metabolism of Debrisoquin can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Debrisoquin.
NicardipineNicardipine may increase the hypotensive activities of Debrisoquin.
NicorandilDebrisoquin may increase the hypotensive activities of Nicorandil.
NifedipineThe serum concentration of Debrisoquin can be decreased when it is combined with Nifedipine.
NiguldipineDebrisoquin may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Debrisoquin can be increased when it is combined with Nilotinib.
NilvadipineDebrisoquin may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Debrisoquin.
NisoldipineNisoldipine may increase the hypotensive activities of Debrisoquin.
NitrazepamThe serum concentration of Debrisoquin can be increased when it is combined with Nitrazepam.
NitrendipineNitrendipine may increase the hypotensive activities of Debrisoquin.
NitroprussideNitroprusside may increase the hypotensive activities of Debrisoquin.
NorethisteroneThe serum concentration of Debrisoquin can be decreased when it is combined with Norethisterone.
ObinutuzumabDebrisoquin may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Debrisoquin.
OlmesartanOlmesartan may increase the hypotensive activities of Debrisoquin.
OmapatrilatOmapatrilat may increase the hypotensive activities of Debrisoquin.
OmeprazoleThe serum concentration of Debrisoquin can be increased when it is combined with Omeprazole.
OxprenololOxprenolol may increase the hypotensive activities of Debrisoquin.
P-NitrophenolThe serum concentration of Debrisoquin can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Debrisoquin can be increased when it is combined with Paclitaxel.
Palmitic AcidThe serum concentration of Debrisoquin can be increased when it is combined with Palmitic Acid.
PanobinostatThe metabolism of Debrisoquin can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Debrisoquin can be increased when it is combined with Pantoprazole.
PargylinePargyline may increase the hypotensive activities of Debrisoquin.
ParoxetineThe serum concentration of Debrisoquin can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Debrisoquin can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololPenbutolol may increase the hypotensive activities of Debrisoquin.
PentoliniumPentolinium may increase the hypotensive activities of Debrisoquin.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Debrisoquin.
PerindoprilPerindopril may increase the hypotensive activities of Debrisoquin.
PhenelzinePhenelzine may increase the hypotensive activities of Debrisoquin.
PheniprazinePheniprazine may increase the hypotensive activities of Debrisoquin.
PhenobarbitalThe serum concentration of Debrisoquin can be decreased when it is combined with Phenobarbital.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Debrisoquin.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Debrisoquin.
PhentolaminePhentolamine may increase the hypotensive activities of Debrisoquin.
PimozideThe serum concentration of Debrisoquin can be increased when it is combined with Pimozide.
PinacidilDebrisoquin may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Debrisoquin.
PirlindolePirlindole may increase the hypotensive activities of Debrisoquin.
PivhydrazinePivhydrazine may increase the hypotensive activities of Debrisoquin.
Platelet Activating FactorThe serum concentration of Debrisoquin can be decreased when it is combined with Platelet Activating Factor.
PolythiazidePolythiazide may increase the hypotensive activities of Debrisoquin.
PonatinibThe serum concentration of Debrisoquin can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Debrisoquin can be increased when it is combined with Posaconazole.
PravastatinThe serum concentration of Debrisoquin can be increased when it is combined with Pravastatin.
PrazosinPrazosin may increase the hypotensive activities of Debrisoquin.
PrednisoneThe serum concentration of Debrisoquin can be increased when it is combined with Prednisone.
ProbenecidThe serum concentration of Debrisoquin can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Debrisoquin can be decreased when it is combined with Progesterone.
PromazineThe metabolism of Debrisoquin can be decreased when combined with Promazine.
PromethazineThe serum concentration of Debrisoquin can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Debrisoquin can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the hypotensive activities of Debrisoquin.
ProtriptylineThe serum concentration of Debrisoquin can be increased when it is combined with Protriptyline.
QuercetinThe serum concentration of Debrisoquin can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Debrisoquin can be increased when it is combined with Quinacrine.
QuinaprilQuinapril may increase the hypotensive activities of Debrisoquin.
QuinidineThe serum concentration of Debrisoquin can be increased when it is combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Debrisoquin.
RamiprilRamipril may increase the hypotensive activities of Debrisoquin.
RanitidineThe serum concentration of Debrisoquin can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Debrisoquin can be increased when it is combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Debrisoquin.
ReboxetineThe serum concentration of Debrisoquin can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Debrisoquin can be increased when it is combined with Regorafenib.
RemikirenRemikiren may increase the hypotensive activities of Debrisoquin.
RescinnamineDebrisoquin may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Debrisoquin.
RifampicinThe serum concentration of Debrisoquin can be decreased when it is combined with Rifampicin.
RilpivirineThe serum concentration of Debrisoquin can be increased when it is combined with Rilpivirine.
RiociguatDebrisoquin may increase the hypotensive activities of Riociguat.
RitonavirThe serum concentration of Debrisoquin can be decreased when it is combined with Ritonavir.
RituximabDebrisoquin may increase the hypotensive activities of Rituximab.
RolapitantThe serum concentration of Debrisoquin can be increased when it is combined with Rolapitant.
RopiniroleThe metabolism of Debrisoquin can be decreased when combined with Ropinirole.
SafrazineSafrazine may increase the hypotensive activities of Debrisoquin.
SaprisartanSaprisartan may increase the hypotensive activities of Debrisoquin.
SaquinavirThe serum concentration of Debrisoquin can be decreased when it is combined with Saquinavir.
ScopolamineThe serum concentration of Debrisoquin can be increased when it is combined with Scopolamine.
SelegilineSelegiline may increase the hypotensive activities of Debrisoquin.
SelexipagDebrisoquin may increase the hypotensive activities of Selexipag.
SertralineThe serum concentration of Debrisoquin can be increased when it is combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Debrisoquin.
SimeprevirThe serum concentration of Debrisoquin can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Debrisoquin can be increased when it is combined with Simvastatin.
SirolimusThe serum concentration of Debrisoquin can be decreased when it is combined with Sirolimus.
SitaxentanDebrisoquin may increase the hypotensive activities of Sitaxentan.
SorafenibThe serum concentration of Debrisoquin can be increased when it is combined with Sorafenib.
SpiraprilSpirapril may increase the hypotensive activities of Debrisoquin.
SpironolactoneThe serum concentration of Debrisoquin can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Debrisoquin can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Debrisoquin can be increased when it is combined with Staurosporine.
StiripentolThe metabolism of Debrisoquin can be decreased when combined with Stiripentol.
StreptozocinThe serum concentration of Debrisoquin can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Debrisoquin can be increased when it is combined with Sulfinpyrazone.
SumatriptanThe serum concentration of Debrisoquin can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Debrisoquin can be increased when it is combined with Sunitinib.
TacrineThe serum concentration of Debrisoquin can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Debrisoquin can be decreased when it is combined with Tacrolimus.
TadalafilTadalafil may increase the antihypertensive activities of Debrisoquin.
TamoxifenThe serum concentration of Debrisoquin can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Debrisoquin can be increased when it is combined with Taurocholic Acid.
TelmisartanTelmisartan may increase the hypotensive activities of Debrisoquin.
TemocaprilDebrisoquin may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Debrisoquin can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Debrisoquin can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Debrisoquin can be decreased when combined with Terbinafine.
TerfenadineThe serum concentration of Debrisoquin can be increased when it is combined with Terfenadine.
TerlipressinTerlipressin may increase the hypotensive activities of Debrisoquin.
TesmilifeneThe serum concentration of Debrisoquin can be decreased when it is combined with Tesmilifene.
TestosteroneThe serum concentration of Debrisoquin can be increased when it is combined with Testosterone.
ThioridazineThe metabolism of Debrisoquin can be decreased when combined with Thioridazine.
TiboloneDebrisoquin may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Debrisoquin can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Debrisoquin can be decreased when combined with Ticlopidine.
TicrynafenTicrynafen may increase the hypotensive activities of Debrisoquin.
TimololTimolol may increase the hypotensive activities of Debrisoquin.
TipranavirThe metabolism of Debrisoquin can be decreased when combined with Tipranavir.
TolazolineTolazoline may increase the hypotensive activities of Debrisoquin.
ToloxatoneToloxatone may increase the hypotensive activities of Debrisoquin.
TolvaptanThe serum concentration of Debrisoquin can be increased when it is combined with Tolvaptan.
TorasemideTorasemide may increase the hypotensive activities of Debrisoquin.
TrandolaprilTrandolapril may increase the hypotensive activities of Debrisoquin.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Debrisoquin.
TranylcypromineTranylcypromine may increase the hypotensive activities of Debrisoquin.
TravoprostTravoprost may increase the hypotensive activities of Debrisoquin.
TrazodoneThe serum concentration of Debrisoquin can be decreased when it is combined with Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Debrisoquin.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Debrisoquin.
TrifluoperazineThe serum concentration of Debrisoquin can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Debrisoquin can be increased when it is combined with Triflupromazine.
TrimazosinDebrisoquin may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Debrisoquin.
TrimethoprimThe serum concentration of Debrisoquin can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Debrisoquin can be increased when it is combined with Trimipramine.
TroleandomycinThe serum concentration of Debrisoquin can be increased when it is combined with Troleandomycin.
UdenafilUdenafil may increase the antihypertensive activities of Debrisoquin.
UnoprostoneDebrisoquin may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Debrisoquin.
VardenafilVardenafil may increase the antihypertensive activities of Debrisoquin.
VenlafaxineThe serum concentration of Debrisoquin can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Debrisoquin can be decreased when it is combined with Verapamil.
VinblastineThe serum concentration of Debrisoquin can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Debrisoquin can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Debrisoquin can be increased when it is combined with Vinorelbine.
XylometazolineDebrisoquin may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Debrisoquin.
ZimelidineThe serum concentration of Debrisoquin can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Debrisoquin can be decreased when combined with Ziprasidone.
Food Interactions
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inducer
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Joyce PI, Rizzi D, Calo G, Rowbotham DJ, Lambert DG: The effect of guanethidine and local anesthetics on the electrically stimulated mouse vas deferens. Anesth Analg. 2002 Nov;95(5):1339-43, table of contents. [PubMed:12401623 ]
  2. Bryan-Lluka LJ, Seers H, Sharpe I: Amezinium and debrisoquine are substrates of uptake1 and potent inhibitors of monoamine oxidase in perfused lungs of rats. Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):536-44. [PubMed:8740147 ]
  3. Mitchell JR, Cavanaugh JH, Arias L, Oates JA: Guanethidine and related agents. 3. Antagonism by drugs which inhibit the norepinephrine pump in man. J Clin Invest. 1970 Aug;49(8):1596-604. [PubMed:5431666 ]
  4. Yi E, Love JA: Alpha-adrenergic modulation of synaptic transmission in rabbit pancreatic ganglia. Auton Neurosci. 2005 Oct 30;122(1-2):45-57. Epub 2005 Aug 25. [PubMed:16126010 ]
  5. Galli A, Blakely RD, DeFelice LJ: Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8671-6. [PubMed:8710929 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Kim RB, Wandel C, Leake B, Cvetkovic M, Fromm MF, Dempsey PJ, Roden MM, Belas F, Chaudhary AK, Roden DM, Wood AJ, Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm Res. 1999 Mar;16(3):408-14. [PubMed:10213372 ]
Comments
comments powered by Disqus
Drug created on September 26, 2007 09:28 / Updated on August 17, 2016 12:24